LOS ANGELES--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) presented preclinical data yesterday on indibulin (ZIO-301) at the American Association of Cancer Research (AACR) meeting in Los Angeles. These data demonstrate that indibulin has distinct biologic and molecular properties from other tubulin binding agents and strongly suggest a very different toxicity profile, particularly with regard to peripheral neuropathy. While indibulin binds to tubulin in general, it does not bind to neuronal specific tubulin and does not disrupt normal axonal microtubules in vitro, likely accounting for the difference with regard to neurotoxicity.
